Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Dietary Supplement: Delayed release capsule, L. reuteri NCIMB 30242, escalated doseDietary Supplement: Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Micropharma Limited
- Target Recruit Count
- 10
- Registration Number
- NCT02216825
Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Dietary Supplement: One-a-Day placebo capsuleDietary Supplement: One-a-Day L. reuteri NCIMB 30242 supplement capsule
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Micropharma Limited
- Target Recruit Count
- 150
- Registration Number
- NCT01630668
- Locations
- 🇨🇦
KGK Synergize Inc., London, Ontario, Canada
Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Dietary Supplement: Cardioviva™ supplement capsuleDietary Supplement: Placebo capsule
- First Posted Date
- 2011-04-26
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Micropharma Limited
- Target Recruit Count
- 131
- Registration Number
- NCT01341613
- Locations
- 🇨🇿
APharma s.r.o., Prague, Czech Republic
Efficacy of Cardioviva™ Probiotic Yogurt Formulation
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Dietary Supplement: Cardioviva™ yogurtDietary Supplement: Placebo yogurt
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Micropharma Limited
- Target Recruit Count
- 150
- Registration Number
- NCT01185795
© Copyright 2025. All Rights Reserved by MedPath